IceCure Medical Ltd. announced that Shero Imaging in St. Louis has installed its ProSense cryoablation system and will begin offering the device to patients with low‑risk breast cancer, making it the first Missouri clinic to provide this minimally invasive treatment.
The ProSense system received FDA marketing authorization in October 2025 for women aged 70 and older with low‑risk tumors or those unsuitable for surgery. The system uses liquid nitrogen to freeze tumors in under 30 minutes, allowing outpatient procedures under local anesthesia.
Dr. Tish Singer, founder of Shero Imaging and a board‑certified breast radiologist, will perform the first procedures. The clinic’s expansion brings advanced, same‑day treatment to a patient population that has limited surgical options, aligning with the FDA indication and addressing a critical unmet need.
For IceCure, adding a U.S. site moves the company closer to a national footprint. The company had previously operated 20 U.S. sites; the new location expands its geographic reach and demonstrates real‑world adoption of its only FDA‑cleared breast cryoablation platform, supporting the company’s growth strategy.
The milestone signals momentum for IceCure’s commercialization plan. By establishing a presence in Missouri, the company taps a new market segment and strengthens its distribution network, positioning it to capture additional patients across the United States and potentially accelerate revenue growth as more sites adopt the technology.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.